March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Comparison of Two intravitreal Ranibizumab Injection Schedules for Polypoidal Choroidal Vasculopathy
Author Affiliations & Notes
  • Young Jung Roh
    Ophthalmology, St Mary's Hospital, Seoul, Republic of Korea
  • Young Gun Park
    Ophthalmology, St Mary's Hospital, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  Young Jung Roh, None; Young Gun Park, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2056. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Young Jung Roh, Young Gun Park; Comparison of Two intravitreal Ranibizumab Injection Schedules for Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2056.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare the efficacy and safety of two different treatment schedules : loading dose and pro re nata (PRN) dosing schedule for polypoidal choroidal vasculopathy (PCV) in Korean.

Methods: : A retrospective chart review was conducted between January, 2007, and July, 2011. These patients had PCV, and received ranibizumab therapy and had completed 12 months of follow up. Patients on LD regimen received three initial monthly intravitreal injections (0.5 mg) of ranibizumab independent of clinical findings. And reinjection after three initial monthly loading was administered on PRN schedule guided by optical coherence tomography(OCT), fluorescein angiography (FAG) and indocyanine green angiography (ICGA) as well as with doctor’s discretion. The main outcome measures were the change of mean best corrected Snellen visual acuity and central macular thickness by OCT, the changes of polyps and branching vascular network by FAG and ICGA, and total number of injections received by patients during the 12 months.

Results: : The LD group contained 34 patients and PRN group contained 23 patients. There were no significant differences between groups in mean changes in visual acuity or central macular thickness. There were no statistical differences in mean change in visual acuity at any time point during the 1, 2, 3, 6 month. However, at the end of 12 months, the LD group significantly improved visual acuity and central macular thickness than the PRN group (p=0.016, 0.027; paired T-test). The mean number of ranibizumab injections was 3.94 in the LD group and 3.09 in the PRN group.

Conclusions: : This study showed that improvement in visual acuity and central macular thickness is best achieved with a loading dose of three monthly injections and higher rate of injections. Further, initial loading doses of three monthly ranibizumab injections are more effective than PRN protocol in treating PCV, with visual and anatomical improvement over one year follow-up.

Keywords: age-related macular degeneration • injection • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×